Comparative Pharmacology
Head-to-head clinical analysis: INTRALIPID 20 versus LIPOSYN II 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTRALIPID 20 versus LIPOSYN II 10.
INTRALIPID 20% vs LIPOSYN II 10%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intralipid 20% is a fat emulsion providing essential fatty acids and triglycerides. It serves as a source of calories and essential fatty acids. In parenteral nutrition, it prevents and treats essential fatty acid deficiency. In lipid rescue therapy for local anesthetic toxicity, it acts as a 'lipid sink' to sequester lipophilic drugs, and may also enhance mitochondrial fatty acid oxidation and improve cardiac contractility.
Provides essential fatty acids (linoleic and linolenic) and calories for patients requiring parenteral nutrition; fatty acids are incorporated into cell membranes and serve as precursors for prostaglandins.
Intravenous infusion at a rate of 0.1 g fat/kg/hour, increasing to 0.5 g fat/kg/hour if tolerated. Maximum daily dose: 2.5 g fat/kg (50 mL/kg/day of 20% emulsion).
Intravenous infusion; maximum daily dose of 2.5 g/kg (25 mL/kg) provided as part of parenteral nutrition, typically administered over 12-24 hours.
None Documented
None Documented
Terminal elimination half-life of lipid particles: approximately 30 minutes for chylomicron-like particles; triglycerides half-life ~15-30 minutes. Clinical context: rapid clearance by lipoprotein lipase.
18–24 hours for clearance of infused triglycerides; terminal elimination half-life of soybean oil emulsion particles is approximately 30 minutes for particles <1 µm, but longer for larger particles (up to several hours); clinical context: prolonged half-life in renal/hepatic impairment.
Renal: negligible. Biliary/fecal: >90% as component of lipid metabolism, excretion via bile and fecal elimination of lipid particles.
Renal: negligible; biliary/fecal: negligible; metabolized in tissues (e.g., muscle, adipose) via beta-oxidation and re-esterification; CO2 production via tricarboxylic acid cycle accounts for majority of elimination.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion